Article
Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
2021-04-12
Abstract excerpt
Nearly one third of men will incur biochemical recurrence after treatment for localized prostate cancer. Androgen deprivation therapy (ADT) is the therapeutic mainstay, however almost all patients will eventually transition to a castrate resistant state (castrate resistant prostate cancer, CRPC). Subjects with CRPC generally develop symptomatic metastatic disease (mCRPC) and incur mortality several years later. Pr...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b89f3a95-7164-5934-8ba0-77c9ed63a4fa
- DOI
- 10.20944/preprints202104.0287.v1
